Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy

Dhanesh Amarnani,1 Arturo Israel Machuca-Parra,1 Lindsay L. Wong,1 Christina K. Marko,1 James A. Stefater,2 Tomasz P. Stryjewski,2 Dean Elliott,2 Joseph F. Arboleda-Velasquez,1 and Leo A. Kim1,2

1Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
2Retina Service, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States

Correspondence: Dean Elliott, Massachusetts Eye and Ear, 243 Charles Street, Boston, MA 02114, USA; dean_elliott@meei.harvard.edu.

Joseph F. Arboleda-Velasquez, Massachusetts Eye and Ear, 20 Stanford Street, Boston, MA 02114, USA; joseph_arboleda@meei.harvard.edu.

Leo A. Kim, Massachusetts Eye and Ear and 243 Charles Street, Boston, MA 02114, USA; leo_kim@meei.harvard.edu.

DA and AIMP contributed equally to the work presented here and should therefore be regarded as equivalent authors.

Submitted: October 13, 2016
Accepted: May 30, 2017


A complication of vitreo-retinal surgery for retinal detachment is a condition known as proliferative vitreoretinopathy (PVR), in which cells grow uncontrollably beneath or on top of the retina.1 These cells, together with the extracellular matrix that they produce, comprise membranes that adhere to the retina and contract, resulting in traction and recurrent retinal detachment. PVR occurs in 5% to 10% of all rhegmatogenous retinal detachment cases, and it is especially prevalent after retinal detachment associated with open globe injury, where it occurs in approximately 50% of cases.2,5

Migration and proliferation of retinal cells, the formation of contractile membranes, and subsequent retinal detachment are hallmarks of PVR.4 This gradual progression of PVR from the presence of vitreous cells to full-thickness retinal folds has been described by the Retina Society classification scheme.5 Currently, the treatment of advanced PVR is vitreo-retinal surgery to remove these tractional membranes.6 There are no specific antiproliferative agents,13–16 antineoplastics,17,18 and anti-inflammatory agents used for the prevention or treatment of PVR.7,8 A variety of pharmacologic agents have been tested for the treatment of PVR including anti-inflammatory drugs,9–12 antiproliferative agents,13–16 antineoplastics,17,18 and anti-growth factor agents,8 and none have demonstrated reproducible clinical success.

Studies from animal models and limited human data indicate that PVR is a complex condition resulting from aberrant migration and proliferation of specific cell types into compartments within the eye where they do not belong.9 The most accepted view of the mechanisms leading to PVR involves migration and proliferation of retinal pigment epithelial (RPE) cells, exposure to cytokines released by retinal trauma, breakdown of the blood–retinal barrier, and infiltration of inflammatory cells.20 This is followed by proliferation and invasion of the intravitreal space with the formation of contractile membranes. Current in vitro models of PVR rely primarily on RPE cell cultures to mimic early PVR, where RPE cells are hypothesized to undergo epithelial to mesenchymal transition (EMT) into fibroblast-like cells.21 In vivo models rely on the injection of a wide variety of cells and factors that are presumed to be involved in PVR membrane formation, including fibroblasts,22,23 RPE,24,25 and blood.26

It is critical to consider that other cell types including glial cells and immune system cells, mainly macrophages, have been shown to play a role in PVR. Specifically, Müller glia has been shown to proliferate inside the retina in PVR cases, and also cells within PVR membranes have been shown to be reactive to glial markers.27,28 Macrophages coming from blood have been
shown to be present in PVR membranes where they are thought to play a significant role in secretion of inflammatory cytokines.\textsuperscript{29, 30} Misregulation of critical signaling molecules including transforming growth factor-\(\beta\) (TGF-\(\beta\))/connective tissue growth factor (CTGF),\textsuperscript{31} a master regulator of fibrosis, and a significant increase in the abundance of proinflammatory molecules including interleukin-1 \(\beta\) (IL-1\(\beta\)) and tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)) are characteristic of PVR and play critical roles in promoting cell growth and extracellular matrix deposition.\textsuperscript{32, 33}

Here, we developed a methodology for isolation and primary culture of cells derived from human PVR membranes, including multiple cell types, and established protocols to use these cultures to examine the cell biology of PVR membranes and to test the efficacy of potential therapies.

**MATERIALS AND METHODS**

**Study Population**

This study was performed at the Schepens Eye Research Institute of Massachusetts Eye and Ear, and research protocols were approved by the Institutional Review Board at Massachusetts Eye and Ear for the collection of surgical specimens and for the retrospective analysis of the clinical data. All research protocols adhered to the tenets of the Declaration of Helsinki, and each patient signed a consent form and Health Information Portability and Accountability Act (HIPAA) authorization before participation within the study.

Six patients were recruited from Massachusetts Eye and Ear who had grade C PVR and were undergoing surgery for repair of retinal detachment and removal of PVR membranes. Patients had to be at least 18 years old and could not be pregnant.

**Human Fundus Photography**

Photographs of patients with PVR were obtained using an ultra-wide field Optos imaging system (Optos, Dunfermline, Scotland).

**Processing of Surgically Removed Human PVR Membranes**

Immediately after surgery, PVR membranes were placed in a specimen cup containing calcium-free and magnesium-free balanced salt solution for transportation. Membranes were divided into pieces under sterile biosafety level 2 conditions to be used for immunohistochemistry or for cell culture.

**Light Microscopy**

Unprocessed PVR membranes were transferred into a culture dish in 1× sterile tissue culture grade phosphate buffered saline (PBS). Phase contrast images were taken using an EVOS FL automated stage live cell imaging system (AMAFD1000R; Life Technologies, Woburn, MA, USA).

**Cell Isolation and Culture of PVR Membranes**

PVR membranes were transferred into 500 \(\mu\)L PBS buffer containing collagenase II (Worthington, Lakewood, NY, USA) and 0.25% bovine calf serum (Hyclone, Logan, UT, USA) and incubated at 37°C for 60 minutes to digest the membrane into a single cell suspension. The membrane was resuspended by gentle pipetting to aid the digestion at a 30-minute time point. Subsequently, the membrane was washed once in Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Walkersville, MD, USA) containing 1% L-glutamine, 5% bovine calf serum (Hyclone), 2.5% wt/vol nystatin, 100 U/mL penicillin G, and 100 \(\mu\)g/mL streptomycin and spun by centrifugation for 3 minutes at 1200 rpm at room temperature. PVR membrane cells (C-PVR) were resuspended in 250 \(\mu\)L PVR medium containing endothelial basal medium 2 (EBM2; Lonza), EGM-2 Bullet Kit, 100 U/mL penicillin, 100 \(\mu\)g/mL streptomycin (Lonza), 2 mM \(t\)-glutamine (Lonza), and 12% fetal bovine serum (FBS; final concentration obtained by adding the serum aliquot included with the EGM-2 Bullet Kit and additional FBS; Atlanta Biologicals, Flowery Branch, GA, USA) and seeded onto 48-well plates.

**Immunohistochemistry of PVR Membranes**

PVR membranes were fixed in 10% formalin in Dulbecco’s PBS (1×; 137 mM NaCl, 2.7 mM KCl, 8 mM Na\(2\)PO\(4\), 1.47 mM KH\(2\)PO\(4\), pH 7.4) overnight at room temperature and stored in PBS at 4°C until paraffin embedding. Serial sections (6 \(\mu\)m) were cut, deparaffinized in 100% xylene, rehydrated in a series of ethanol, and washed in PBS. Sections were processed for immunohistochemistry using the following antibodies: \(\alpha\) smooth muscle actin (1:100; Dako, Carpinteria, CA, USA), glial fibrillary acidic protein (GFAP) (1:500; Dako), cytokertatin (1:250; Abcam, Cambridge, UK), Bestrophin-1 (BEST-1; 1:150; Abcam), and CD14 (1:50; Abcam). Slides were incubated in 3% H\(2\)O\(_2\) in methanol to block endogenous peroxidases, and then heat-induced epitope retrieval was performed according to manufacturer’s instructions and as described previously.\textsuperscript{34, 35} Slides were then blocked in TNB protein blocking solution (Perkin Elmer, Waltham, MA, USA) and incubated in primary antibody overnight at 4°C. The following day, slides were incubated with biotinylated secondary antibody and then incubated in alkaline phosphatase–conjugated avidin (Vectastain ABC-AP Universal Kit; Vector Laboratories, Burlingame, CA, USA). Expression of markers was visualized using the Vector Red chromogenic substrate kit (Vector Laboratories) and counterstained using Gill no. 3 hematoxylin (Sigma-Aldrich Corp., St. Louis, MO, USA).

**Induction of Invasive Phenotype in Culture**

C-PVR cells grew as a confluent monolayer on 48-well plates and were cultured in PVR medium. A transformation from a monolayer to invasive cell clusters was triggered by switching P1 cultures from PVR medium to a differentiation medium containing xMEM, N1 supplement, taurine (250 \(\mu\)g/mL), hydrocortisone (20 ng/mL), triodo-thyronin (13 pg/mL), and 5% FBS for 72 hours. Membranes grown in vitro by incubation of C-PVR cells with this conditional medium were harvested and fixed in 10% formalin in PBS overnight prior to paraffin embedding and immunohistochemistry as described above.

**Immunofluorescence**

Cells from PVR membranes were seeded on a four-well Chamber Slide System for 24 to 72 hours (Thermo Fisher Scientific, Waltham, MA, USA). Cells were fixed with 4% paraformaldehyde (PFA) for 10 minutes, washed with PBS, permeabilized with 0.25% Triton X-100 in PBS for 5 minutes, and blocked (10% goat serum in PBS) for 1 hour. To identify specific cell types, C-PVR was incubated with a fluorescein isothiocyanate (FITC)-conjugated monoclonal anti-\(\alpha\) smooth muscle actin (1:150; Sigma-Aldrich Corp.), rabbit polyclonal anti-GFAP primary antibody (glial fibrillary acidic protein, 1:150; Dako), rabbit anti-\(\alpha\)SMA primary antibody (smooth muscle actin, 1:150; Sigma-Aldrich Corp.), and rabbit anti-cytokeratin antibody (1:200; Abcam). Cells were incubated with the primary antibody overnight at August 2017 Vol. 58 No. 10 3941
4°C followed by incubation with goat anti-rabbit Alexa Fluor 594 secondary antibody (1:300; Life Technologies) or with goat anti-mouse Alexa Fluor 488 secondary antibody (1:300; Life Technologies) for 2 hours at room temperature. Cells were washed with PBS three times, and coverslips were mounted onto the chamber slides using a Prolong Gold antifade reagent (Life Technologies). Images were obtained using a Zeiss Axioskop 2 MOT Plus microscope (Carl Zeiss, Inc., Oberkochen, Germany).

**Assessing Effects of Methotrexate on C-PVR Cells**

Thirty thousand C-PVR cells were plated in 48-well plates. The next day, C-PVR cells were washed with PBS and treated with PVR media alone (control) or in PVR media with methotrexate (MTX; 100, 200, or 400 μM). Sigma-Aldrich using triplicates for each condition. PVR media were replaced every 72 hours, and the cells were washed with PBS before media change for 6 weeks. Cultures were fixed with 4% paraformaldehyde for 10 minutes prior to staining. Cell nuclei were labeled with Hoechst 33342 diluted in PBS 1:200 (ImmunoChemistry Technologies, LLC, Bloomington, MN, USA). Nuclei were counted using ImageJ software (National Institutes of Health). Positive cells for apoptosis were counted manually. The quantification of cell density is reported as the average of cells per high-powered field of human PVR cultures, which were cultured in triplicate.

**Assessment of Proliferation**

C-PVR cells were cultured on cover slips at a confluence of 30,000 cells per well and treated with different concentrations of MTX (100, 200, and 400 μM) or vehicle. At the 24-, 48-, and 72-hour time points, cells were washed and fixed with 4% PFA for 10 minutes. Cells were permeabilized with 0.5% Triton X-100 in PBS for 5 minutes and blocked (10% goat serum in PBS) for 1 hour at room temperature. Proliferation was evaluated by incubating cells with anti-Ki67 antibody (1:50; Novus Biologicals, Cambridge, United Kingdom). The primary antibody was prepared in antibody dilution buffer (5% goat serum) and incubated overnight at 4°C. Cells were incubated with goat anti-rabbit Alexa Fluor 594 secondary antibody (Life Technologies) or with goat anti-mouse Alexa Fluor 488 secondary antibody (Life Technologies) for 2 hours at room temperature. Images were obtained using an antibody against Ki67, a proliferation marker used as described above. The TScratch Matlab module (ETH Zurich, Zurich, Switzerland) was used to perform the scratch wound assay. For this experiment, cells were exposed to specific treatments: PVR media alone (control), 0.2% BSA in water (vehicle), 400 μM MTX, 1 ng/mL TNF-α, 1 ng/mL TNF-α plus 400 μM MTX, 10 ng/mL TNF-α, and 10 ng/mL TNF-α plus 400 μM MTX. Images were taken 0, 6, 12, 24, 48, 72, and 96 hours after wounding. All the experiments were performed in triplicate, and migration was measured as the percentage of scratch closure related to time 0 using the TScratch Matlab module (ETH Zurich, Zurich, Switzerland).

**Correlating Proliferation of PVR Membranes and C-PVR**

Cell proliferation of PVR membranes and C-PVRs from clinical cases 3 and 5 was determined by immunofluorescence staining using an antibody against Ki67, a proliferation marker used as described above. Primary antibody rabbit anti-human Ki67 antibody (1:100; Novus Biologicals) and cell nuclei were labeled with Hoechst 33342 diluted in PBS 1:200 (ImmunoChemistry Technologies).

**Assessment of Caspase-Mediated Apoptosis**

Cell death of C-PVR cells treated with MTX was measured using fluorochrome-labeled inhibitor of caspases-3 and caspase-7 (FAM FLICA CASPASE 3&7 Assay kit; ImmunoChemistry Technologies). Three different time points were tested: 2, 4, and 6 weeks. After each time point, cells were protected from light and pretreated with fluorescent-labeled inhibitor of caspases (FLICA) compound and PVR media for 1 hour at 37°C and 5% CO₂. Following incubation, the cell nuclei were stained with Hoechst 33342 diluted in PVR media 1:200 (ImmunoChemistry Technologies) for 10 minutes at 37°C; cultures were washed with EBM2 media and fixed with 4% PFA for 10 minutes. Nuclei were counted using Image J software (National Institutes of Health). Positive cells for apoptosis were counted manually. The quantification of cell density is reported as the average of cells per high-powered field of human PVR cultures, which were cultured in triplicate. The quantification of apoptosis is reported as the percentage of positive cells for apoptosis.

**Scratch Wound Assay and TNF-α Effect on C-PVR Cells**

To detect and measure cell migration, 6 × 10⁵ C-PVR were cultured in 12-well plates. Cultures were maintained 5 to 6 days to permit formation of a confluent monolayer. The monolayer was scratched with a sterile 200-μL pipette tip, and a single wound was generated per well. Cells were washed with PBS to remove debris and then exposed to the specific treatment: PVR media alone (control) or in PVR media with MTX (100, 200, or 400 μM). Images were taken 0, 6, 12, 24, 48, 72, and 96 hours after wounding. All the experiments were performed in triplicate, and migration was measured as the percentage of scratch closure related to time 0 using the TScratch Matlab module (ETH Zurich, Zurich, Switzerland).

**Imaging**

Images for immunohistochemistry of PVR membranes, assessing effects of MTX on C-PVR cells, the scratch wound assay, and the TNF-α effect on C-PVR cells were taken using an EVOS FL automated stage live cell imaging system (Life Technologies). All the experiments were performed in triplicate, and migration was measured as the percentage of scratch closure related to time 0 using the TScratch Matlab module.

**Statistical Analysis**

Experiments were repeated at least three times and included at least three technical replicates. Statistical analyses were performed using the GraphPad Prism 5 software (GraphPad, Inc., La Jolla, CA, USA). Statistical significance was tested by multiple ANOVA and Tukey’s test for group comparison. Data are presented as the mean ± SEM. P < 0.05 was considered statistically significant.

**Results**

**Clinical Demographics**

Six patients with grade C PVR that required surgical excision were enrolled in the study. The demographics of the patients are summarized in the Table. All patients had recurrent
rhegmatogenous retinal detachment due to PVR. One patient had a recent history of a zone 3 open globe injury with rhegmatogenous retinal detachment and retinal incarceration in the scleral wound. This patient underwent vitrectomy, but returned with recurrent rhegmatogenous retinal detachment due to PVR.

A total of six grade C PVR membranes were surgically excised from patients with retinal detachment (Fig. 1A) and processed in the laboratory. Under light microscopy, PVR membranes

\begin{table}
\centering
\begin{tabular}{|l|c|c|l|l|l|}
\hline
Patient ID & Age, y & Sex & Cause of Retinal Detachment & Type of Retinal Detachment & Class of PVR & Preoperative Visual Acuity & Final Postoperative Visual Acuity \\
\hline
PVR-01 & 73 & Male & Spontaneous & Recurrent macula-off rhegmatogenous retinal detachment & C & 20/80 & 20/40 \\
PVR-02 & 76 & Female & Traumatic open globe injury, zone 3 & Recurrent macula-off rhegmatogenous retinal detachment & C & Hand motions & Counting Fingers \\
PVR-03 & 32 & Female & Spontaneous & Recurrent macula-on rhegmatogenous retinal detachment & C & Hand motions & 20/150 \\
PVR-04 & 67 & Female & Spontaneous & Recurrent macula-off rhegmatogenous retinal detachment & C & Hand motions & 20/125 \\
PVR-05 & 63 & Male & Spontaneous & Recurrent macula-on rhegmatogenous retinal detachment & C & Hand motions & Counting Fingers \\
PVR-06 & 40 & Female & Spontaneous & Recurrent macula-off rhegmatogenous retinal detachment & C & Counting Fingers & 20/125 \\
\hline
\end{tabular}
\caption{Clinical Demographics}
\end{table}

Six patients with grade C-PVR were recruited, and cells were grown in culture to develop C-PVR membranes. RD, retinal detachment.

Characterization by Immunohistochemistry of PVR Membranes and C-PVR

A total of six grade C PVR membranes were surgically excised from patients with retinal detachment (Fig. 1A) and processed in the laboratory. Under light microscopy, PVR membranes

\begin{figure}
(A) Fundus photograph of the left eye of a patient, case 6 (PVR-06) with recurrent retinal detachment; note presence of a gas bubble within the eye from previous retinal surgery. There is a band of pigmented PVR along the inferior arcade (outlined by white lines). Also note inferior retinal holes in area of detached retina (white arrows). (B) Phase contrast view of the PVR membrane after surgical excision from PVR-06. Scale bar denotes 500 \( \mu \)m. (C) C-PVR cells from case 3 (PVR-03) after 1 week in culture. (D) After 4 weeks in culture, note the formation of bands between the membrane and the rim of the culture dish. (E) C-PVR cells from case 5 (PVR-05) were similarly confluent after 1 week. (F) After 4 weeks in culture, cells grew on top of each other with loss of cell contact inhibition. Scale bar denotes 100 \( \mu \)m. (G–U) Light micrographs of PVR membranes from three different cases (PVR-02, PVR-03, and PVR-05) using primary antibodies (all in red) against SMA (G–I), GFAP (J–L), CD14 (M–O), BEST-1 (P–R), cytokeratin (S–U), and counterstained with hematoxylin (blue). Scale bar denotes 100 \( \mu \)m.
grossly appeared to consist of pigmented and nonpigmented cells embedded in a fibrous matrix (Fig. 1B). We examined the cellular constituents of PVR membranes using immunohistochemistry in specimens PVR-02, PVR-03, and PVR-05. Staining of these samples revealed positive localization of SMA, a marker of myofibroblasts, and CD14, a marker expressed by most tissue macrophages, displayed more robust expression in PVR-02 compared with PVR-03. BEST-1, a marker for RPE cells, did not show expression in PVR-02 yet was localized to the pigmented cells of PVR-03, suggesting these cells were derived from the RPE. Both cytokeratin, found in epithelial cells, and GFAP, found in astrocytes, were not expressed in PVR-02, whereas PVR-03 showed low expression for both markers. Interestingly, PVR-05 showed positive signal for all these markers (Figs. 1G–1U).

Establishment of C-PVR Primary Cultures

Cells from these PVR membranes, which we called C-PVR, were successfully isolated in each case and cultured as described in the Methods section (Figs. 1C–1F; Supplementary Fig. S2). Distinct populations of C-PVR cells contained pigmented granules characteristic of RPE cells (Fig. 1B). SMA-positive cells were abundant in C-PVR derived from PVR-03, PVR-04, and PVR-05 but not from PVR-02 (Figs. 2A–2D), suggesting the presence of myofibroblasts in culture. Other cell populations, including GFAP-positive cells, were also identified in the cell culture for PVR-02, PVR-03, and PVR-04 (Figs. 2E–2G), with nonspecific staining of PVR-05 (Fig. 2H), suggesting the presence of stellate shaped glial cells. Cytokeratin was positive for all cells in culture for PVR-03 and PVR-05 but was rare in PVR-02 and PVR-04 (Figs. 2I–2L), whereas F4-80, a marker for macrophages and microglial cells, was positive in PVR-03 and PVR-05 but negative in PVR-02 and PVR-04 cultures (Figs. 2M–2P). These findings suggest that C-PVR cells retain the expression of some markers expressed in the patient-derived tissue.

We observed that a culture medium containing 12% FBS, heparin, insulin-like growth factor (IGF), fibroblast growth factor (FGF), ascorbic acid, hydrocortisone, epithelial growth factor (EGF) and vascular endothelial growth factor (VEGF) (PVR medium) induced growth and survival of C-PVR cultures (Supplementary Fig. S2J). Unknown serum factors were required because C-PVR growth was reduced in PVR medium lacking serum (Supplementary Fig. S2B). After 4 weeks in culture, human cells from clinical cases 3 and 5 (PVR-03 and PVR-05) grew rapidly and displayed distinct morphologic characteristics and growth behavior in culture (Figs. 1C and 1E, respectively). After 1 week of culture, PVR-03 formed a confluent monolayer. After 4 weeks of culture in PVR

**Figure 2.** Characterization of cultured cells by immunofluorescence. Immunofluorescence of C-PVR cells from four different cases using primary antibodies against (A–D) SMA all in green, (E–H) GFAP all in red, (I–L) cytokeratin (intermediate filaments in epithelial cells) all in green, and (M–P) F4/80 (immune cells) all in red and counterstained with DAPI (blue). Scale bar denotes 100 μm.
medium, these cells formed bands that appeared analogous to contractile bands found in patients with PVR (Fig. 1D). Similarly, C-PVR from clinical case 5 (PVR-05) grew over 1 week to form a confluent monolayer. However, when grown over 4 weeks, these cells appeared to grow on top of one another, forming a distinct membranous structure but no bands (Fig. 1F).

Remarkably, PVR membranes and their corresponding C-PVRs showed congruent levels of proliferation measured with the Ki67 marker (Supplementary Fig. S3).

**In Vitro Membrane Formation by C-PVR**

C-PVR recapitulated key features of human PVR under specific culture conditions. Initially, pigmented granules characteristically found in RPE cells were released from C-PVR cells after 48–72 hours in culture (Fig. 3A, 3B). In addition, PVR cells can form invasive membranes that break into the vitreous. Accordingly, C-PVR cells grew as a confluent monolayer on transwells in EBM-2 culture medium supplemented with SingleQuots Kit (Lonza) and 12% FBS (Figs. 1C–1F, 3B; Supplementary Fig. S1). A transformation from a monolayer to invasive cell clusters was triggered by switching to a differentiation culture medium. The phenotypic change was reversible by switching back to the growth medium. Scale bar denotes 500 µm. (D) PVR membrane from clinical case 3 was processed for immunohistochemistry using the antibody against SMA in red and counterstained with hematoxylin (blue). Scale bar denotes 100 µm. (E) Immunofluorescence of the C-PVR primary cultures showing positive cells for SMA in green, suggesting that this molecular marker is retained in C-PVR primary cultures. Nuclei are counterstained with DAPI. Scale bar denotes 100 µm. (F) Cell cluster shown in (C) was harvested and processed for immunocytochemistry using antibody against SMA. Scale bar denotes 100 µm.

**Assessing Effects of MTX on C-PVR Cells**

To assess the potential of C-PVR cultures in drug screening, we examined the response of these cells to MTX, a robust inhibitor of cell proliferation and inflammation.44 We found that MTX significantly reduced C-PVR band formation, cell number (Fig. 4) and proliferation (Fig. 5 and Supplementary Fig. S4). Interestingly, when we treated C-PVR cells with different concentrations of dexamethasone and daunorubicin, two drugs previously used as potential treatments for PVR,45–47 we did not see a significant reduction in proliferation (Supplementary Fig. S5). To determine whether inhibition of band formation was due to MTX effects on cell migration, we performed scratch wound healing assays. However, we found that MTX treatment at different concentrations had no effect on migration induced by our standard culture conditions (Supplementary Fig. S6) or migration induced by TNF-α treatment (1 and 10 ng/mL), a factor that has been identified in high concentrations in the vitreous during the active phase of PVR (Supplementary Fig. S7).

Last, we examined whether cell death contributed to the effects of MTX on C-PVR. Increasing concentrations of MTX (100, 200, and 400 µM) triggered significant cell death over time; little effect was observed after 2 weeks of exposure (Supplementary Fig. S8), whereas significant cell death was
FIGURE 4. Effect of MTX on cell density and band formation of C-PVR. Phase contrast and Hoechst-stained immunofluorescence images of C-PVR cells from PVR-03 after 6 weeks of culture without MTX (A–C) and with 100 (D–F), 200 (G–I), and 400 μM (J–L) MTX. (M) Graph shows quantification of cell density after treatment with different concentrations of MTX or control. Error bars represent SEM. Scale bar denotes 100 μm.

FIGURE 5. Effect of MTX on proliferation of C-PVR cells. Immunofluorescence images of C-PVR cells after 24, 48, and 72 hours without (A, E, I) and with 100 (B, F, J), 200 (C, G, K), and 400 mM (D, H, L) MTX. Quantification of proliferation by Ki67 immunofluorescence (red) at 24, 48, and 72 hours (M–O, respectively). Error bars represent SEM. Scale bar denotes 100 μm.
observed after 4 (Supplementary Fig. S5) and 6 weeks of treatment (Fig. 6) compared with controls.

**DISCUSSION**

Here we report the isolation, characterization, and culture of cells from patient-derived PVR membranes, a common complication of retinal detachment. PVR-derived primary cultures, which we call C-PVR, grow robustly and reproduce key features of human PVR including band formation and invasiveness under specific culture conditions. As a demonstration of experimental feasibility, we show that MTX, a commonly used US Food and Drug Administration–approved drug, can significantly inhibit proliferation and induce death of C-PVR, whereas migration was not impacted by MTX treatment. In contrast, both dexamethasone and daunorubincin (two drugs that have previously been proposed for the treatment of PVR) did not affect C-PVR proliferation. Thus, C-PVR can potentially be used for testing in vitro the efficacy of therapies and to screen for new compounds capable of halting PVR.

PVR remains one of the most common postoperative complications after retinal detachment repair. Although many investigators have proposed pathobiological mechanisms leading to the disease, little progress has been made toward developing an effective treatment. One of the major limitations has been the lack of a definite model system of the human disease for in vitro and in vivo analyses. The most widely used in vitro models involved monocultures of RPE that aim to reproduce specific aspects of PVR including EMT, proliferation, and migration. An immortalized RPE cell line derived from a human PVR was also previously reported. Our methodology complements these previous studies by providing protocols for the generation of robust primary cultures from PVR membranes (C-PVR cells) obtained from patients immediately after surgery. This heterogeneous mixture of cells, including RPE-derived cells, glial cells, and macrophages, likely represents the late manifestations of the disease as they were obtained from patients with grade C PVR membranes. This mixed population of cells may recapitulate the PVR “ecosystem” where RPE-derived cells, glia, and macrophages cohabitate and interact with each other.

In our model system, MTX was an effective inhibitor of C-PVR growth. MTX also halted band formation and invasiveness, features that make the disease clinically devastating. MTX is an antimetabolite and antifolate drug that has been used for cancer treatment since the 1950s. It is also indicated for treatment of autoimmune diseases such as rheumatoid arthritis. Other mechanisms of action involve direct effects on inflammatory pathways, in particular, neutralization of the effects of TNF-α and IL-1β, although the molecular mechanisms underlying these effects remain largely uncharacterized.

The work reported here describes a model system for the study of human PVR based on the generation of primary cell cultures from human PVR composed of mixed cell populations. When used in drug screens, this added level of complexity may be beneficial at identifying potential therapies likely to work in preclinical and clinical trials for PVR.

**ACKNOWLEDGMENTS**

Massachusetts Eye and Ear has filed a patent application for the use of methotrexate to prevent PVR. Dean Elliott and Tomasz Stryjewski are shareholders in Helio Vision, Inc., which has licensed the patent.

**Figure 6.** Effect of MTX on C-PVR survival. Hoechst-stained immunofluorescence images of C-PVR cells from PVR-05 after 6 weeks of culture without MTX (A–C) and with 100 (D–F), 200 (G–I), and 400 μM (J–L) MTX. (M) Quantification of cell density showing a significant reduction in cell density after 2, 4, and 6 weeks under the treatment with MTX. (N) Quantification of apoptosis showing a significant increase in the presence of Caspases 3 and 7 after different time points (2, 4, and 6 weeks) with MTX. Error bars represent SEM. Scale bar denotes 100 μm.
Presented in part at the Military Health System Research Symposium, Boston, MA, USA, August 18, 2015.

The authors thank Patricia D’Amore, Eric Ng, and Magali Saint-Geniez for valuable discussions and advice.

Supported by National Institutes of Health Grants R00EY021624 (JFA-V), K12EY16355 (LAK), and R21EY027061 (LAK). Foundation support from the E. Matilda Ziegler Foundation for the Blind (LAK); a Karl Kirchgessner Foundation research grant (LAK); Department of Ophthalmology, Harvard Medical School (JFA-V and LAK); National Institutes of Health PS3 Center Core Grant P50EY03790. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Vision Research Program Technology/Therapeutic Development Award under Award No. W81XWH-17-2-0006. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

Disclosure: D. Amarnani, None; A.I. Machuca-Parra, None; L.L. Wong, None; C.K. Marko, None; J.A. Stefater, None; T.P. Stryjewski, P; D. Elliott, F; J.F. Arboleda-Velasquez, None; L.A. Kim, None

References

27. Fisher SK, Lewis GP. Muller cell and neuronal remodeling in retinal detachment and reattachment and their potential consequences for visual recovery: a review and reconsideration of recent data. *Vision Res*. 2003;43:887–897.
31. Bochaton-Piallat ML, Kapetanios AD, Donati G, Redard M, Gabbiani G, Pourraas CJ. TGFBeta1, TGFBeta receptor II and ED-A fibronectin expression in myofibroblast of vit-


42. Anlauf E, Derouiche A. Glutamine synthetase as an astrocytic marker: its cell type and vesicle localization. Front Endocrinol (Lausanne). 2013;4:144.


